Malignant Pleural Mesothelioma, Solid Tumors
Conditions
Keywords
malignant pleural mesothelioma, solid tumors
Brief summary
The phase I part of the study is a dose-finding study of escalating doses of CBP501 combined with full-dose cisplatin and pemetrexed in patients with histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or would otherwise be eligible for cisplatin and pemetrexed as first-line therapy. The maximum tolerated dose (MTD) will be determined based on DLTs occurring during the first treatment cycle. Pharmacokinetics of the triplet combination will be assessed during the phase I part of the trial. The phase II part will evaluate full-dose cisplatin and pemetrexed combined with CBP501 (at the MTD determined in the phase I part) in previously untreated, unresectable malignant pleural mesothelioma patients. Patients will be randomized in a 2 : 1 ratio to pemetrexed, cisplatin and CBP501 (Arm A) or to pemetrexed and cisplatin (Arm B); randomization will be stratified according to histology and performance status.
Detailed description
This is an open-label, multicenter, international, phase I-II study. The phase I part, a dose-finding study of escalating doses of CBP501 combined with fixed full-dose cisplatin and pemetrexed, has been completed and results are presented in this report. MTD was determined on DLT occurring during the first cycle. This phase I part was evaluated in a patient population with advanced solid tumors The phase II part will evaluate full-dose cisplatin and pemetrexed combined with CBP501 at the MTD determined in the phase I part. Patients will be randomized in a 2:1 ratio to pemetrexed, cisplatin and CBP501 (Arm A) or pemetrexed and cisplatin (Arm B). This phase II part will be evaluated in chemotherapy-naïve patients with malignant pleural mesothelioma Randomization will be stratified by: * Histology: epithelial vs other (sarcomatoid or biphasic) * Performance status: 0-1 vs 2
Interventions
DRUGpemetrexed, cisplatin and CBP501
CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP. Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL. Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration.
Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL. Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration.
DRUGpemetrexed, cisplatin and CBP501, dose finding
Dose level 1: CBP501 16 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Dose level 2: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP. Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL. Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration.
Sponsors
CanBas Co. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent obtained prior to initiation of any study-specific procedures 2. Phase I: Histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or would otherwise be eligible for cisplatin and pemetrexed as first-line therapy Phase II: Histologically or cytologically confirmed diagnosis of malignant pleural mesothelioma (MPM), not amenable for radical resection, who has not received previous chemotherapy or other systemic treatment 3. Measurable disease according to the modified Response Evaluation Criteria in Solid Tumors (RECIST, see below) 4. Male or female patients aged at least 18 years 5. ECOG Performance Status (PS): 0-2 6. Previous anticancer treatment must be discontinued at least 3 weeks prior to first dose of study treatment (6 weeks for mitomycin C; 6 weeks for anti-androgen therapy if discontinued prior to treatment initiation, with the exception of 8 weeks for bicalutamide) 7. Life expectancy greater than 3 months 8. Adequate organ function 9. Female patients of child-bearing potential must have a negative pregnancy test and be using at least one form of contraception as approved by the Investigator for 4 weeks prior to the study and 4 months after the last dose of study drug. For the purposes of this study, child-bearing potential is defined as: All female patients unless they are post-menopausal for at least one year or are surgically sterile 10. Male patients must use a form of barrier contraception approved by the investigator during the study and for 4 months after the last dose of study drug 11. Ability to cooperate with the treatment and follow-up
Exclusion criteria
1. Radiation therapy to more than 30% of the bone marrow prior to entry into the study 2. Phase II only: Mesothelioma originating outside the pleura (e.g.: peritoneum) 3. Absence of measurable lesions 4. The patient has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the opinion of the investigator. 5. Any previous history of another malignancy within 5 years of study entry (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix) 6. Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance 7. Evidence of peripheral neuropathy \> grade 1 according to NCI-CTCAE Version 3 8. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry 9. Pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception 10. Known HIV, HBV, HCV infection 11. Presence of CNS metastases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin | End of study | Planned: Forty-two patients were to be treated in Arm A. If ≥ 23 patients (\>54%) were free of progression and death at 4 months, then the study regimen would be considered for further evaluation in this indication. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Pemetrexed, Cisplatin, and CBP501: Phase 2 pemetrexed, cisplatin and CBP501
pemetrexed, cisplatin and CBP501: CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.
Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.
Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration. | 40 |
| Pemetrexed and Cisplatin: Phase 2 pemetrexed and cisplatin
pemetrexed and cisplatin: Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.
Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration. | 23 |
| Pemetrexed, Cisplatin, and CBP501: Phase 1 DL1: CBP501 16mg/m2, Alimta 500mg/m2, cisplatin 75mg/m2 DL2: CBP501 25mg/m2, Alimta 500mg/m2, cisplatin 75mg/m2 | 6 |
| Total | 69 |
Baseline characteristics
| Characteristic | Pemetrexed, Cisplatin, and CBP501: Phase 2 | Pemetrexed and Cisplatin: Phase 2 | Pemetrexed, Cisplatin, and CBP501: Phase 1 | Total |
|---|---|---|---|---|
| Age, Continuous | 63 years STANDARD_DEVIATION 10.03 | 66.3 years STANDARD_DEVIATION 12.1 | 62.8 years STANDARD_DEVIATION 13.61 | 64.2 years STANDARD_DEVIATION 10.86 |
| Sex: Female, Male Female | 8 Participants | 3 Participants | 1 Participants | 12 Participants |
| Sex: Female, Male Male | 32 Participants | 20 Participants | 5 Participants | 57 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 40 | 1 / 23 | 4 / 6 |
| other Total, other adverse events | 28 / 40 | 15 / 23 | 6 / 6 |
| serious Total, serious adverse events | 21 / 40 | 13 / 23 | 5 / 6 |
Outcome results
Primary
4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin
Planned: Forty-two patients were to be treated in Arm A. If ≥ 23 patients (\>54%) were free of progression and death at 4 months, then the study regimen would be considered for further evaluation in this indication.
Time frame: End of study
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pemetrexed, Cisplatin, and CBP501 | 4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin | 4M PFS by Independent Image Review | 25 participants |
| Pemetrexed, Cisplatin, and CBP501 | 4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin | 4M PFS by Site assess | 27 participants |
| Pemetrexed and Cisplatin | 4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin | 4M PFS by Independent Image Review | 9 participants |
| Pemetrexed and Cisplatin | 4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin | 4M PFS by Site assess | 13 participants |